DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DBD - US2536512021 - Common Stock
68.875 USD
+0.08 (+0.12%)
DBD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 35 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has only an average score on both its financial health and profitability. DBD is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year DBD was profitable.
In the past year DBD had a positive cash flow from operations.
DBD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
1.2 Ratios
DBD has a Return On Assets of 1.36%. This is in the better half of the industry: DBD outperforms 62.86% of its industry peers.
DBD's Return On Equity of 4.57% is fine compared to the rest of the industry. DBD outperforms 74.29% of its industry peers.
The Return On Invested Capital of DBD (8.85%) is better than 71.43% of its industry peers.
DBD had an Average Return On Invested Capital over the past 3 years of 5.12%. This is significantly below the industry average of 15.26%.
The 3 year average ROIC (5.12%) for DBD is below the current ROIC(8.85%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROIC | 8.85% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
With a decent Profit Margin value of 1.37%, DBD is doing good in the industry, outperforming 62.86% of the companies in the same industry.
The Operating Margin of DBD (7.47%) is better than 77.14% of its industry peers.
DBD's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 25.48%, DBD is doing worse than 60.00% of the companies in the same industry.
DBD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DBD is destroying value.
DBD has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, DBD has less shares outstanding
Compared to 1 year ago, DBD has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 1.97 indicates that DBD is not a great score, but indicates only limited risk for bankruptcy at the moment.
DBD's Altman-Z score of 1.97 is in line compared to the rest of the industry. DBD outperforms 51.43% of its industry peers.
The Debt to FCF ratio of DBD is 3.71, which is a good value as it means it would take DBD, 3.71 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.71, DBD is in the better half of the industry, outperforming 68.57% of the companies in the same industry.
A Debt/Equity ratio of 0.84 indicates that DBD is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.84, DBD is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Altman-Z | 1.97 |
ROIC/WACC0.94
WACC9.38%
2.3 Liquidity
A Current Ratio of 1.36 indicates that DBD should not have too much problems paying its short term obligations.
The Current ratio of DBD (1.36) is comparable to the rest of the industry.
A Quick Ratio of 0.89 indicates that DBD may have some problems paying its short term obligations.
DBD's Quick ratio of 0.89 is in line compared to the rest of the industry. DBD outperforms 54.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The earnings per share for DBD have decreased strongly by -38.07% in the last year.
DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 69.69% yearly.
DBD shows a decrease in Revenue. In the last year, the revenue decreased by -2.86%.
The Revenue has been decreasing by -3.18% on average over the past years.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
3.2 Future
The Earnings Per Share is expected to grow by 19.21% on average over the next years. This is quite good.
DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.51% yearly.
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 18.82, which indicates a rather expensive current valuation of DBD.
71.43% of the companies in the same industry are more expensive than DBD, based on the Price/Earnings ratio.
DBD's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.59.
DBD is valuated correctly with a Price/Forward Earnings ratio of 14.01.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DBD indicates a somewhat cheap valuation: DBD is cheaper than 62.86% of the companies listed in the same industry.
DBD's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.82 | ||
| Fwd PE | 14.01 |
4.2 Price Multiples
DBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DBD is cheaper than 94.29% of the companies in the same industry.
DBD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DBD is cheaper than 82.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.82 | ||
| EV/EBITDA | 7.6 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
DBD's earnings are expected to grow with 19.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.13
PEG (5Y)N/A
EPS Next 2Y12.85%
EPS Next 3Y19.21%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:DBD (12/26/2025, 1:29:00 PM)
68.875
+0.08 (+0.12%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.36%
Inst Owner Change-2.66%
Ins Owners1.82%
Ins Owner Change0%
Market Cap2.47B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price TargetN/A
Short Float %2.41%
Short Ratio4.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)4.41%
PT rev (3m)4.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.47%
EPS NY rev (1m)13.35%
EPS NY rev (3m)20.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.82 | ||
| Fwd PE | 14.01 | ||
| P/S | 0.67 | ||
| P/FCF | 9.82 | ||
| P/OCF | 8.84 | ||
| P/B | 2.23 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.6 |
EPS(TTM)3.66
EY5.31%
EPS(NY)4.92
Fwd EY7.14%
FCF(TTM)7.01
FCFY10.18%
OCF(TTM)7.79
OCFY11.31%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)2.13
PEG (5Y)N/A
Graham Number50.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROCE | 11.2% | ||
| ROIC | 8.85% | ||
| ROICexc | 9.91% | ||
| ROICexgc | 29.15% | ||
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% | ||
| FCFM | 6.82% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 20.59% | ||
| Cap/Sales | 0.75% | ||
| Interest Coverage | 2.89 | ||
| Cash Conversion | 68.06% | ||
| Profit Quality | 497.23% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.97 |
F-Score7
WACC9.38%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y14.01%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%
DIEBOLD NIXDORF INC / DBD FAQ
What is the fundamental rating for DBD stock?
ChartMill assigns a fundamental rating of 4 / 10 to DBD.
What is the valuation status for DBD stock?
ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.
What is the profitability of DBD stock?
DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.
How financially healthy is DIEBOLD NIXDORF INC?
The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.
Can you provide the dividend sustainability for DBD stock?
The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.